Emicizumab prophylaxis in haemophilia patients older than 50 years with cardiovascular risk factors: Real‐world data-Reference-Cited by-同舟云学术

Emicizumab prophylaxis in haemophilia patients older than 50 years with cardiovascular risk factors: Real‐world data

Published:2021-02-17 Issue:2 Volume:27 Page:253-260
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Misgav Mudi¹²,Brutman‐Barazani Tami¹²,Budnik Ivan³,Avishai Einat¹²,Schapiro Jonathan¹²,Bashari Dalia¹²,Barg Assaf A.¹²^ORCID,Lubetsky Aaron¹²,Livnat Tami¹²^ORCID,Kenet Gili¹²^ORCID

Affiliation:

1. National Hemophilia Center Sheba Medical center Tel Hashomer Israel

2. Amalia Biron Research Institute of Thrombosis and Hemostasis Sackler School of Medicine Tel Aviv University Tel Aviv Israel

3. Department of Pathophysiology First Moscow State Medical University (Sechenov University)

Funder

Roche

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.14261

Reference30 articles.

1. Mortality and causes of death in Italian persons with haemophilia, 1990-2007

2. Hemophilia A in the third millennium

3. Clinical management of older persons with haemophilia

4. A cross-sectional analysis of cardiovascular disease in the hemophilia population

5. Factor VIII–Mimetic Function of Humanized Bispecific Antibody in Hemophilia A

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the effects of Factor Xa inhibitors on thrombin generation in people with haemophilia;Thrombosis Research;2024-05

2. Emicizumab is well tolerated and effective in people with congenital hemophilia A regardless of age, severity of disease, or inhibitor status: a scoping review;Research and Practice in Thrombosis and Haemostasis;2024-05

3. Emicizumab is efficacious in people with hemophilia A with comorbidities aged ≥50 years: analysis of 4 phase III trials;Research and Practice in Thrombosis and Haemostasis;2024-03

4. Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B;Cochrane Database of Systematic Reviews;2024-02-27

5. Safety of recombinant activated factor VII for treatment of breakthrough bleeds in patients with congenital haemophilia A and inhibitors receiving emicizumab prophylaxis: Review of the real‐world evidence;Haemophilia;2024-01-30